The panelists discuss the critical shift from seizure-focused management to targeting the underlying genetic etiology of Dravet syndrome, drawing on natural history data that shows developmental impairment progresses independently of seizure control.
Three epileptologists set the stage on Dravet syndrome, exploring the biological underpinnings of the disease, the cascading burden it places on patients and families, and why this condition demands far more than seizure management.
Two experts explain the impact of the drug fenfluramine’s FDA approval in the treatment of Dravet syndrome.
Drs Thiele and Wirrell continue analyzing the benefits of cannabidiol as a therapeutic option for patients with Dravet or Lennox-Gastaut syndromes.
The director of pediatric epilepsy and professor of neurology at Mayo Clinic details the rampant acceleration of telemedicine and how her practice is adjusting to the COVID-19 pandemic.
